Introduction
Use of Implantable Cardioverter Defibrillators (ICD) have revolutionized the care of patients with ischemic and non-ischemic cardiomyopathy. 1, 2 The primitive ICD introduced in the 1980s by Mirowski and colleagues has become much more sophisticated with programming capabilities, atrial and left ventricular leads, antitachycardia pacing (ATP) algorithms, bi-ventricular pacing and cardioverting and defibrillating shocks. 1, 3 Similarly, indications for ICD implantation are expanding as well. 4 Assessment for eligibility of an ICD implantation is considered one of the integral parts of management of cardiomyopathy patients due to mortality benefits. 1, 2 Consequently, the number of ICD implantations has increased significantly in the last decade with a concurrent decrease in the use of stand-alone antiarrhythmic drugs for ventricular arrhythmia indications. [5] [6] [7] The ICD prevents sudden cardiac death (SCD) by terminating the episodes of ventricular tachycardia (VT) or ventricular fibrillation (VF), delivering ATP therapy or ICD shock. Therefore, patients with ICD typically receive one or more ICD therapies for spontaneous arrhythmias following implantation. 1, 8 Despite the technological evolution of ICD systems, more than 20% of shocks that are delivered are due to supraventricular arrhythmia and are categorized as "inappropriate". [9] [10] [11] ICD shocks are physically and emotionally painful and most patients dread future shocks. 12 Many patients experience symptoms such as dizziness, palpitations, nervousness, flushing or even syncope before receiving an ICD shock. 13 A higher incidence of depression and poor quality of life has been reported in patients who have received one of more ICD shocks, and adverse psychological outcomes directly correlate to the number of ICD shocks. [14] [15] [16] Several anti-arrhythmic drugs have been shown to reduce ICD therapies including shocks. Upward of 70% patients end up receive adjuvant antiarrhythmic drug therapy for this indication. 17, 18 This was best exemplified in the device arm of the Antiarrythmic versus Implantable Defibrillator (AVID) trial. 19 About 18% patients in the ICD arm of the AVID trial had to be started on adjuvant antiarrhythmic drug therapy (amiodarone 42%, sotalol 21%, and mexiletine 20%) to reduce frequent ICD shocks and to prevent recurrent ventricular arrhythmia. 19 Adjuvant antiarrhythmic drug therapy in these crossover patients reduced the one year arrhythmia event rate from 90% to 64%. Potential benefits, pitfalls, need for caution and the clinical trials of adjuvant antiarrhythmic drugs in ICD implanted patients will be discussed in this review.
Clinical trials supporting the efficacy of adjuvant antiarrhythmic drug therapy
Major clinical trials establishing the role of adjuvant antiarrhythmic drugs and their principle outcomes are listed in table 1. The majority of patients enrolled in these trials received an ICD for secondary prevention of SCD or a documented episode of VT/VF.
Sotalol was one of the first antiarrhythmic drugs tested for such an indication by Pacifico et al. 20 In this double-blind prospective multicenter trial, 302 patients with ICDs were randomized to receive either 160-320 mg of d,l-sotalol (n=151) or matching placebo (n=151) and were followed for 12 months. In this study, compared to placebo, treatment with sotalol led to a 48% risk reduction of all-cause mortality and delivery of first shock for any reason ( Figure 1 shown to be effective in increasing the median time to first all-cause ICD shocks in a study by O'Toole et al. 27 However, dofetilide administration was associated with a high incidence of TdP in this study.
Although most of the patients with ICDs receive β-blockers as part of a comprehensive medical regimen, it is worth underscoring the importance of β-adrenergic blockade in prevention of ICD shocks. Simple β-blockers have been shown to be at least equally or more effective than sotalol in the prevention of ICD shocks. In a small prospective trial of 100 patients with an existing ICD, Kettering et al showed that metoprolol was as effective as sotalol in preventing VT/VF and resultant ICD interventions. 23 Similarly, in a post hoc analysis of 691 patients with ischemic cardiomyopathy in the Multicenter Automatic Defibrillator Implantation Trial II (MADIT-II), patients receiving higher doses of metoprolol, atenolol and carvedilol had a 52% relative risk reduction for recurrent VT/VF requiring ICD therapy as compared to patients not on β-blockers. Superior efficacy of metoprolol to sotalol was demonstrated in a small prospective study of 70 patients with an ICD. 22 The probability of reaching a combined end point of symptomatic recurrence of fast VT or VF, or death was significantly lower at 1 and 2 years in the metoprolol group (83% and 74% respectively) as compared to the sotalol group (47% and 38% respectively, p = 0.004). ICD interventions in the form of ATP and shocks were significantly lower in the metoprolol compared to the sotalol arm.
Azimilide is a novel class III drug that blocks both the rapid and slow component of the delayed rectifier cardiac potassium current, and is effective in a variety of supraventricular arrhythmias. 28 by 37% and 55% respectively as compared to placebo. These beneficial effects of azimilide translated into reduced emergency department visits and hospitalizations. 29 Azimilide was well tolerated as an addition to conventional therapy. About 86% patient were on concomitant β-blocker therapy suggesting that benefits of azimilide were over and above traditional therapy. The overall incidence of adverse events and rates of early discontinuation (35-36%) were similar to placebo. [24] [25] [26] Azimilide therapy led to a dose dependent prolongation of the QT interval, however, TdP was reported in 5 patients without any consequences 25 One patient had severe but reversible neutropenia with 75 mg of azimilide. 25 In the context of the above data, azimilide is the first drug submitted to the Food and Drug Administration for use with an ICD and is currently under review to be used for this indication.
Amiodarone remains one of the most commonly used antiarrhythmic drugs, especially in patients with advanced cardiomyopathy due to its established efficacy and cardiac safety profile compared to other antiarrhythmic drugs. The OPTIC (Optimal Pharmacologic Therapy in Cardioverter Defibrillator Patients) study investigated the efficacy of β-blocker, sotalol and β-blocker plus amiodarone in the prevention of ICD shocks. 26 The OPTIC investigators randomized 412 patients with an ICD to receive β-blocker alone, sotalol alone, and amiodarone in addition to β-blocker and followed them for one year. The results showed that the patients treated with sotalol or amiodarone had reduced risk of shock of 56% compared to β-blocker alone. In addition, amiodarone plus β-blocker was more effective than β-blocker alone (HR = 0.27, p < 0.001) or sotalol (HR: 0.43, p = 0.02) in preventing both appropriate and inappropriate ICD shocks ( Figure 3 ).
Mortality was not significantly different among the three groups and no cases of TdP were reported. Rates of study drug discontinuation at 1 year were 18.2% for amiodarone, 23.5% for sotalol and 5.3% for β-blocker alone group. Adverse pulmonary, thyroid, and bradycardic events were more common with amiodarone treatment.
Similar to its congener amiodarone, dronedarone was effective in reducing the rate of appropriate ICD intervention during a 30 day follow-up in a small study.
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Benefits of Adjuvant antiarrhythmic drug therapy
Clearly, antiarrhythmic drugs reduce the incidence of both appropriate as well as inappropriate ICD therapies (both ATP and Shock) by more than half. 20, 25, 26 Such a reduction in ICD shocks would be expected to decrease emergency department visits as well as the rate of hospitalization. 25, 29 A decrease in the number of ICD discharges also prolongs the battery life of the device. 31 As such, antiarrhythmic drug therapy result in overall improvement in quality of life of ICD implanted patients. Additionally, most antiarrhythmic drugs tend to prolong the tachycardia cycle length and may render the tachycardia more hemodynamically stable and thus amenable to termination with ATP. 32 Some antiarrhythmic drugs may reduce the defibrillation threshold (DFT) and facilitate defibrillation of VT/VF as discussed below.
About 10 to 30% patients with ICD develop electrical storm, defined as three or more episodes of hemodynamically destabilizing VT/VF occurring in a 24-hour period.
Development of electrical storm is associated with increased morbidity, and a 40% 3-month mortality. [33] [34] [35] Although, recent clinical trials have suggested role of catheter ablation techniques as a first line treatment for electrical storm, antiarrhythmic drugs still remain the cornerstone for the therapy for electrical storm. Reversal of precipitating factors, optimization of β-blocker therapy and addition of intravenous amiodarone followed by oral maintenance dosing is required in most cases to abort and prevent recurrent ventricular arrhythmia. 33, 36 As outlined above, the investigational agent azimilide has been shown to reduce risk of electrical storm by 37-55%. 37 The principle advantages of adjuvant antiarrhythmic drug therapy can be summarized as in Table 1 .
Drug-device Interaction
A great deal of caution needs to be exercised when a new antiarrhythmic drug is started in a patient with an implanted device. Potential adverse drug-device interactions are listed in Table 2 .
One of the most important drug-device interactions is a drug-induced increase in defibrillation and pacing thresholds leading to failure of treatment of life threatening arrhythmia. Although most antiarrhythmic drugs increase the defibrillation threshold (DFT), some may lower it. In a sub-study of 94 patients from OPTIC, amiodarone plus β-blocker therapy led to a small but statistically significant increase (1.29 J) in DFT after 8-13 weeks of therapy. 38 In contrast, treatment with sotalol and β-blocker was associated with decrease in DFT by 0.89 J and 1.67 J respectively. Careful testing of DFTs should be performed in all the patients, with special attention to those who have monophasic waveform ICDs, those with an epicardial lead system 39 , patients with a high DFT at baseline, and patients treated with high dose, 40 chronic amiodarone. [41] [42] [43] [44] Azimilide has been shown to have minimal effects on the DFT or pacing thresholds in ICD patients. 24, 45 Similarly, dronedarone has been shown to have no effect on defibrillation safety margin or pacing thresholds at its therapeutic dose or higher. 30, 46 Antiarrhythmic drugs are usually increase the cycle length of VT, which improve hemodynamic tolerability and effectiveness of ATP in most situations. The downside is that the drugs like amiodarone and sotalol may slow the tachycardia rate to such a degree that it becomes lower that the programmed tachycardia detection rate of the ICD leading to failure to sense VT. 47 Appropriate adjustments in the detection algorithm are necessary when adjuvant antiarrhythmic drugs are instituted. Antiarrhythmic drugs, especially Class IC agents, may also affect the morphology of the QRS complex and thus impact morphology sensing and rhythm stability criterion leading to incorrect rhythm interpretation by the ICD and resultant inappropriate treatment. 48 Drug induced proarrhythmia, especially TdP, is rare but serious problem when drugs with Class III effects like azimilide, sotalol, dofetilide and amiodarone are used, especially in patients with compromised repolarization reserve. 49 Extra-cardiac side effects of antiarrhythmic drugs like amiodarone are a limitation to its long term use. This may be less of an issue with new drugs like dronedarone or azimilide.
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Expert Opinion
In conclusion, adjuvant antiarrhythmic drug therapy should be considered an 
